

1 A mathematical model for Zika virus
2 transmission with Optimal Control

3 Santosh Kumar Sharma ^{*1} and Nawin Kumar Agrawal²

4 ¹Department of Mathematics, K. L. S. College, Nawada, Magadh University, Bodh
5 Gaya, Bihar-805110, India

6 ²Department of Mathematics, L N Mithila University, Darbhanga Bihar 846008,
7 India

8 October 16, 2023

9 **Abstract**

10 In this research, we developed a mathematical model to study the co-
11 interaction of the Zika virus (a vector-borne disease). We qualitatively
12 analyzed the model and established the necessary conditions under which
13 disease-free and endemic equilibria are asymptotically stable. We qualita-
14 tively analyzed the model and established the necessary conditions under
15 which disease-free and endemic equilibria are asymptotically stable. There
16 are only two possible equilibrium points in our system, two of which are
17 endemic and one of which is devoid of disease. The disease-free equilib-
18 rium is shown by the theoretical study to be both locally and globally
19 asymptotically stable if the basic reproduction number is less than one.
20 The most sensitive factors of the analyzed Zika model are the number
21 of times susceptible (infected) individuals were bitten by susceptible (in-
22 fected) mosquitoes, the host population's awareness rate, and the recovery
23 rates of susceptible (infected) humans. The World Health Organisation
24 has classified the current Zika virus (ZIKV) pandemic as a worldwide
25 public health emergency. Concerns include the lack of effective diagnos-
26 tic tests and vaccinations, the wide geographic range of mosquito species
27 that can spread the virus, and the lack of population immunity in recently
28 impacted nations.

29 **Keywords:** Zika virus, Reproduction number, Optimal control, Stability anal-
30 ysis, equilibrium point.

31 **1 Introduction**

32 Zika is a mosquito-borne virus that was initially discovered in a Rhesus macaque
33 monkey in Uganda in 1947. Infection and sickness in people were then discovered

*Corresponding author. Email: santoshmumath@gmail.com

34 in other African nations in the 1950s. Between the 1960s and the 1980s, isolated
35 cases of human infections were reported from Asia and Africa. However, since
36 2007, epidemics of the Zika virus infection have been documented in Africa,
37 the Americas, Asia, and the Pacific. When the Zika virus first emerged in the
38 Americas, a link between infection and microcephaly (a smaller-than-normal
39 head size) was first noticed.

40 The WHO declared a Public Health Emergency of International Concern
41 (PHEIC) in relation to microcephaly, other neurological disorders, and the Zika
42 virus as soon as the link between the Zika virus and congenital malformations
43 was confirmed. In India, Zika virus epidemic activity was discovered in 2021.
44 Although 89 nations and territories have yet to report evidence of Zika virus
45 infection brought on by mosquitoes, worldwide surveillance is still insufficient.
46 Symptoms of the Zika virus in most infected individuals are rare. If they develop,
47 they often begin 3–14 days after infection, are minor in nature, include rash,
48 fever, conjunctivitis, muscle and joint pain, malaise, and headache, and last
49 2–7 days on average. In tropical and subtropical areas, *Aedes* (*Stegomyia*)
50 genus mosquitoes, especially *Aedes aegypti*, are the major vectors of Zika virus
51 transmission.

52 In the course of the day, *Aedes* mosquitoes typically bite. Along with trans-
53 mitting urban yellow fever, these mosquitoes also spread dengue and chikun-
54 gunya. People who experience rashes, fevers, or joint discomfort should obtain
55 plenty of rest, drink lots of water, and use antipyretics and/or analgesics to
56 relieve their symptoms. Patients should seek medical attention and counseling
57 if their symptoms get worse. Pregnant women who live in Zika transmission
58 regions or who exhibit signs of the virus should consult a doctor for clinical
59 treatment, laboratory testing, education, and other services. Protection against
60 mosquito bites throughout the day and early evening is a vital step in avoiding
61 Zika virus infection, especially among pregnant women, women who are trying
62 to get pregnant, and young children. Examples of personal safety precautions
63 include dressing in clothing that covers as much of the body as possible and is
64 ideally light in color;

65 Recent studies, how the human and mosquito populations how the virus
66 spreads. The study by Ali et al [2], According to the studies by Gonzalez-Parra
67 Gilberto, et al [9], The Zika virus can be contained more effectively with the
68 help of educational programs and pesticide use. The study by Bernhauerov
69 et al [4], provided a numerical characterization of in vitro ZIKV infection and
70 contributed to a better understanding of the dynamics of ZIKV-host cell in-
71 teractions. A mathematical model and cost-effectiveness analysis to compare
72 different control strategies and emphasize the need for accurate implementation
73 of optimal control measures. by the studies, Wanget al. [18], In the study of
74 Aldila et al. [1], it was discovered that when R_0 is greater than 1, a local asymp-
75 tote, or endemic equilibrium point, exists. Reducing the impact of Zika on the
76 neighborhood may be possible with the addition of a class of asymptomatic car-
77 riers and the use of control measures. The studies of Khan et al. [11], According
78 to Bonyah et al. [6], studied the best strategies to control a co-infection model
79 while using the center manifold theory to examine the dynamics of a system.

80 Transmission dynamics between humans and mosquitoes, the impact of vaccina-
81 tion, and the effectiveness of different control strategies. In the study by Sharma
82 et al [16], The ideal control system employing prevention, treatment, and pesti-
83 cide spraying is determined by the stability analysis of the model's fixed points.
84 By the studies, Alzahrani et al [3], By the studies, Biswas et al. [5] provide cal-
85 culations and analysis to comprehend the dynamics of the virus in populations
86 of both humans and mosquitoes. Rezapour et al. [15] found that the fractional-
87 order Caputo derivative is what transmits the Zika virus between people and
88 mosquitoes. According to the study, Nwalozie et al. [13] better preventative,
89 control, and management measures are needed to decrease the consequences of
90 the Zika virus on world health. Studies by Mello et al. [7] show that baculovirus
91 expression technology is used in insect cell cultures to create vaccines against
92 arboviruses, such as ZIKV.

93 These techniques are being used by WHO to stop the Zika virus. who It
94 assists nations in confirming epidemics, offers technical assistance and direction
95 for the efficient control of disease outbreaks brought on by mosquitoes, looks into
96 the development of new tools, such as pesticide products and application tech-
97 nology, develops evidence-based strategies for managing attacks and solutions,
98 and assists nations in confirming epidemics with the assistance of its network of
99 cooperating laboratories.

100 Two areas where mathematical models have a big impact are the dynamics
101 of infectious diseases and the development of improved techniques to halt their
102 spread in the future. Using mathematical models, the dynamic is anticipated,
103 and this helps to create more efficient techniques for stopping its spread in the
104 future.

105 The numerical findings of our study were produced using built-in MATLAB
106 functions since we were more concerned with analyzing the qualitative dynam-
107 ical behaviors of the model under discussion than with the precision, rate of
108 convergence, etc. of the generated numerical solutions. Additionally, we have
109 created an optimum control issue for the system, where the objectives are to
110 reduce immunization and boost revenue.

111 In this study, we proposed epidemiological models for the Zika virus that
112 consider the virus' antigenic changes. In the models for transmission, specifics
113 on changes to the amino acid sequences of the HA proteins at epitope regions
114 were included. First, using the sequencing data, we calculated the rate of time-
115 varying antigenic change for each Zika virus subtype. Finally, we demonstrated
116 how changes in viral antigenicity may drastically influence the dynamics of Zika
117 virus transmission at the population level. In light of this, we suggested epi-
118 demiological models for the Zika viruses. We therefore proposed epidemiological
119 models for the Zika virus.

120 The article is organized as follows. In part 2, which is the section after this
121 one, we create the mathematical model. Fundamental characteristics like well-
122 posedness, nonnegativity, boundedness, etc. are examined in Section 3. Analysis
123 of equilibrium and stability is discussed in Section 4. Section 5 presents the topic
124 of best control. The discussion in Section 6 concludes the essay.




Figure 1: Schematic diagram of the model (1)

2 Formulation of Zika Virus Epidemic Model

The transmission model with media coverage is given by the following deterministic system of nonlinear ordinary differential equations

$$\begin{aligned}
 \frac{dS}{dt} &= \Lambda + \omega V - \frac{\beta SI}{1 + pI} - (\mu + \theta)S, \\
 \frac{dI}{dt} &= \frac{\beta SI}{1 + pI} + \frac{\beta' VI}{1 + pI} - (\mu + \alpha)I, \\
 \frac{dV}{dt} &= \theta S - (\mu + \omega)V - \frac{\beta' VI}{1 + pI}, \\
 \frac{dR}{dt} &= \alpha I - \mu R.
 \end{aligned} \tag{1}$$

where the initial conditions are

$$S = S_0, \quad I = I_0, \quad V = V_0, \quad R = R_0. \tag{2}$$

In this model, Λ is the constant production, ω is the [], β is Transmission rate, p is Haf saturation constant, μ is Death rate, θ is Rate of vacillation, α is Rate of infected, and β' is Disseses transmission after vacillation. The schematic explanation of our proposed model is displayed in Figure 1. The values of the parameters of the model (1) are given in Table (1).

3 Stability of the equilibrium states

(A) The disease-free equilibrium of the system (1) is given by

$$E^0 = (S^0, I^0, V^0, R^0) = \left(\frac{\Lambda(\mu + \omega)}{\mu(\mu + \omega + \theta)}, 0, \frac{\Lambda\theta}{\mu(\mu + \omega + \theta)}, 0 \right). \tag{3}$$

136 (B) The endemic equilibrium of the system (1) is given by

$$E^* = (S^*, I^*, V^*, R^*),$$

137 It satisfies $S^* > 0$, $I^* > 0$, $V^* > 0$, $R^* > 0$ and

$$\begin{aligned} S^* &= \frac{Y_1 - (\Lambda + \omega V^*)}{(\mu + \theta)}, \\ I^* &= \frac{(Y_1 + Y_2)}{(\mu + \alpha)}, \\ V^* &= \frac{(\theta S^* - Y_2)}{(\mu + \alpha)}, \\ R^* &= \frac{\alpha I^*}{\mu}. \end{aligned} \tag{4}$$

138 where,

$$Y_1 = \frac{\beta S^* I^*}{(1 + pI^*)} \text{ and } Y_2 = \frac{\beta' V^* I^*}{(1 + pI^*)}.$$

139 Substituting the above into the second equation at equilibrium will yield the
140 expression for I after some rearrangement. For illustration,

141 4 Basic reproduction number of the model

142 The local stability of the system E^0 is governed by the basic reproduction num-
143 ber $R_0 < 1$. The basic reproduction number is the average number of new
144 secondary infections in entirely susceptible Zika virus produced by a single in-
145 fected Zika virus. With the help of the next generation method [17], we can
146 calculate the basic reproduction number. For this method, we consider the
147 model variables in such a manner that the compartments reflect only infected
148 individuals. By this assumption, we have $y = (S, I, V, R)$, where I are the
149 infected compartments. Furthermore, \mathcal{G}_H denotes the set of all infection-free
150 states—that is,

$$\mathcal{X}_H = \{X \geq 0 : X_i, i = 1, 2\}. \tag{5}$$

151 System (1) is rewritten as

$$X'_i = h_i(X) = \mathcal{F}_i(X) - \mathcal{G}_i(X), \quad i = 1, 2, \tag{6}$$

152 where $\mathcal{F}_i(X)$ describes the rate of appearance of new infections in compartment
153 i . Moreover,

$$\mathcal{Y}_i(X) = \mathcal{G}_i^-(X) - \mathcal{G}_i^+(X), \tag{7}$$

154 $\mathcal{Y}_i^+(X)$ is the transmission rate into the compartment i , and $\mathcal{Y}_i^-(X)$ is the
155 rate of transmission out of this compartment. The subsequent norms are to be
156 modeled.

157 (B₁) $\mathcal{F}_i(X) \geq 0$, $\mathcal{G}_i^-(X) \geq 0$, $\mathcal{G}_i^+(X) \geq 0$, for any $X \geq 0$;

158

159 (B₂) If $X_i = 0$, then $\mathcal{G}_i^- = 0$;

160

161 (B₃) $\mathcal{F}_i = 0$, for $i = 2$;

162

163 (B₄) If $X \in \mathcal{X}_H$, then $\mathcal{F}_i(X) = 0$, $\mathcal{G}_i^+(X) = 0$, for $i = 1, 2$;

164

165 (B₅) For the disease-free equilibrium (DFE) X_0 , the Jacobi matrix $Dh(X_0)$
166 constrained to the subspace $h = 0$ has all negative eigenvalues.

167 To formulate the next generation matrix FG^{-1} [17] from matrices of partial
168 derivatives of \mathcal{F}_i and \mathcal{G}_i . Specifically,

$$F = \left[\frac{\partial \mathcal{F}_i(X_0)}{\partial X_j} \right], \quad G = \left[\frac{\partial \mathcal{G}_i(X_0)}{\partial X_j} \right], \quad (8)$$

169 where $i, j = 1, 2$. Here, F, G are two-dimensional squared matrices and $R_0 =$
170 $\varrho(FG^{-1})$ (ϱ denotes a spectral radius of the matrix). For model (1), we have

$$\mathcal{F} = \begin{pmatrix} \frac{\beta SI}{1+pI} + \frac{\beta' VI}{(1+pI)} & 0 \\ 0 & 0 \end{pmatrix}, \quad \mathcal{G} = \begin{pmatrix} (\mu + \alpha)I & 0 \\ -\alpha I + \mu R & \mu \end{pmatrix}. \quad (9)$$

171 Next, we are setting that the entry-wise non-negative new infection matrix
172 is F . Let the non-singular Metzler matrix [12] define the transitions of Zika
173 virus infection between the infection compartments and the matrices, which are
174 given as follows.

$$F = \begin{pmatrix} \frac{\beta S}{(1+pI)^2} + \frac{\beta' V}{(1+pI)^2} & 0 \\ 0 & 0 \end{pmatrix}, \quad G = \begin{pmatrix} \mu + \alpha & 0 \\ -\alpha & \mu \end{pmatrix},$$

$$G^{-1} = \begin{pmatrix} \frac{1}{(\mu + \alpha)} & 0 \\ \frac{\alpha}{\mu(\mu + \alpha)} & \frac{1}{\mu} \end{pmatrix}.$$

175 We observe that G^{-1} is also an entry-wise non-negative matrix and thus
176 FG^{-1} is an entry-wise non-negative next-generation matrix showing the ex-
177 pected number of new infections which is given by

$$FG^{-1} = \begin{bmatrix} \frac{\beta S}{(1+pI)^2} + \frac{\beta' V}{(1+pI)^2} & 0 \\ 0 & 0 \end{bmatrix} \times \begin{bmatrix} \frac{1}{(\mu + \alpha)} & 0 \\ \frac{\alpha}{\mu(\mu + \alpha)} & \frac{1}{\mu} \end{bmatrix},$$

$$= \begin{bmatrix} \frac{\beta S + \beta' V}{(1+pI)^2(\mu + \alpha)} & 0 \\ 0 & 0 \end{bmatrix}. \quad (10)$$

Table 1: Parameters and their associated sensitivity indices along with the relative percentage impact on the threshold quantity (R_0)

Parameter	Definition	Value	Reference
Λ	Birth rate		
ω			
β	Transmission rate		
p	Haf saturation costant		
μ	Death rate		
θ	Rate of vacillation		
α	Rate of infected		
β'	Disseses transmission after vacillation		

178 Using the spectral radius of the next-generation matrix [10, 17], for the sys-
 179 tem (1), we find the basic reproduction number R_0 , which is the largest eigen-
 180 value of FG^{-1} at E^0 . Thus,

$$\begin{aligned} \mathcal{R}_0 &= \frac{\beta S + \beta' V}{(\mu + \alpha)}, \\ &= \frac{\beta S \mu (\mu + \omega + \theta) + \beta' \Lambda \theta}{\mu (\mu + \alpha) (\mu + \omega + \theta)}. \end{aligned} \quad (11)$$

181 **Theorem 1.** *The system (1) describes the spreading kinetics of Zika virus*
 182 *infection, which has a threshold parameter basic reproduction number $R_0 =$*
 183 *$\frac{\beta S \mu (\mu + \omega + \theta) + \beta' \Lambda \theta}{\mu (\mu + \alpha) (\mu + \omega + \theta)}$ at E^0 . For $R_0 > 1$, the system (1) has a unique positive*
 184 *endemic steady state.*

185 5 Local stability of the disease-free equilibrium

186 **Theorem 2.** *The disease-free equilibrium E^0 is locally asymptotically stable if*
 187 *$R_0 < 1$, and unstable if $R_0 > 1$.*

188 *Proof.* The Jacobian of the system (1) evaluated at E^0 is given by

$$J_{E^0} = \begin{pmatrix} -(\mu + \theta) & -\beta S & \omega & 0 \\ 0 & \beta S + \beta' V - (\mu + \alpha) & 0 & 0 \\ \theta & -\beta' V & -(\mu + \omega) & 0 \\ 0 & \alpha & 0 & -\mu \end{pmatrix}. \quad (12)$$

189 Here the eigenvalues are $[\lambda = -\mu, \{(\beta S + \beta' V) - (\mu + \alpha)\}]$ and the other
 190 two eigenvalues are determined from the given equation

$$\begin{vmatrix} -(\mu + \theta) - \lambda & \omega \\ \theta & -(\mu + \omega) - \lambda \end{vmatrix} = 0 \quad (13)$$

191 and the characteristic equation for (13) is

$$A_0\lambda^2 + A_1\lambda + A_2\lambda = 0. \quad (14)$$

192 where,

$$A_0 = 1 > 0, \quad A_1 = (\omega + \theta + 2\mu), \quad A_2 = (\mu^2 + \mu\theta + \mu\omega).$$

193 Now, it is easy to note that $A_0 \geq 0$, and $A_1 > 0$. If $A_0 > 0$, then all the
 194 roots of Equation (4) will be negative (Section 3.3 in [10]). If $A_2 > 0$, then we
 195 have threshold criteria to determine the stability condition at the infection-free
 196 point E^0 . We have the condition $\mu_1 + 2\frac{p\tilde{H}_S}{H_T} < \nu < \frac{\mu_2\mu_3}{\beta_1\tilde{H}_S}$, which implies that
 197 $R_0 < 1$ and results in the eradication of infection. \square

198 5.1 Local stability of the endemic equilibrium:

199 **Theorem 3.** *The system (1) around E^* is locally asymptotically stable (LAS)*
 200 *if $R_0 > 1$.*

201 *Proof.* We already established that the equilibrium E^* is feasible when $R_0 > 1$.
 202 Now, the Jacobi matrix around E^* is

$$|J_{E^*} - \lambda| = \begin{pmatrix} a_{11} - \lambda & a_{12} & a_{13} & 0 \\ a_{21} & a_{22} - \lambda & 0 & 0 \\ a_{31} & a_{32} & a_{33} - \lambda & 0 \\ 0 & a_{42} & 0 & a_{44} - \lambda \end{pmatrix}. \quad (15)$$

203 where,

$$\begin{aligned} a_{11} &= -\frac{\beta I}{(1+pI)} - (\mu + \theta), & a_{12} &= -\frac{\beta S}{(1+pI)^2}, \\ a_{21} &= \frac{\beta I}{(1+pI)}, & a_{22} &= \frac{\beta S + \beta'V}{(1+pI)^2} - (\mu + \alpha), \\ a_{32} &= -\frac{\beta'V}{(1+pI)^2}, & a_{33} &= -(\mu + \omega) - \frac{\beta' I}{(1+pI)}, \\ a_{13} &= \omega, & a_{31} &= \theta, & a_{42} &= \alpha, & a_{44} &= \mu. \end{aligned}$$

204 At E^* , the characteristic equation is

$$\lambda^4 - x_1\lambda^3 + x_2\lambda^2 + x_3\lambda + x_4\lambda^0 = 0. \quad (16)$$

205 where,

$$\begin{aligned} x_1 &= (a_{33} + a_{44} + a_{11} + a_{22}), \\ x_2 &= (a_{33}a_{44} + a_{11}a_{33} + a_{22}a_{44} + a_{11}a_{22}), \\ x_3 &= (a_{33}a_{44} - a_{11}a_{22}a_{33} - a_{11}a_{22}a_{44}), \\ x_4 &= (a_{11}a_{22}a_{33}a_{44}). \end{aligned}$$

206 By the Routh-Hurwitz criteria at the endemic equilibrium E^* , the system (1)
 207 is LAS if $R_0 > 1$. \square

208 **6 Global Stability**

209 **Theorem 4.** *The system is globally asymptotically stable (GAS) when $R_0 < 0$.*

210 *Proof.* We consider the Lyapunov function as follows:

$$L_1 = \xi_1 I + \xi_2 V + \xi_3 R. \quad (17)$$

211 Differentiating the Lyapunov function $L_1(17)$ with respect to t , we find

$$\begin{aligned} \frac{dL_1}{dt} &= \xi_1 \frac{dI}{dt} + \xi_2 \frac{dR}{dt} \\ &= \xi_1 \left[\frac{\beta SI}{(1+pI)} + \frac{\beta' VI}{(1+pI)} - (\mu + \alpha)I \right] + \xi_2(\alpha I - \mu R) \end{aligned} \quad (18)$$

212 When $R_0 < 1$, we have $\frac{dL_1}{dt} < 0$ and $\frac{dL_1}{dt} = 0$ implies that $R = 0$. From the
213 model (1), we can say that $I = 0$ when $R = 0$ in the limit $t \rightarrow 0$. Hence, ac-
214 cording to the Lyapunov–LaSalle theorem, the system is globally asymptotically
215 stable when $R_0 < 1$. This completes the proof. \square

216 **Theorem 5.** *The endemic equilibrium E^* is globally asymptotically stable (GAS)
217 if $R_0 > 1$.*

218 *Proof.* Let us consider the Dulac function:

$$D(S, I, V, R) = \frac{1}{(S I V R)}, \quad (19)$$

219 and denote the R.H.S of equations in the system (1) as

$$\begin{aligned} Z_1 &= \Lambda + \omega V - \frac{\beta SI}{1+pI} - (\mu + \theta)S, \\ Z_2 &= \frac{\beta SI}{1+pI} + \frac{\beta' VI}{1+pI} - (\mu + \alpha)I, \\ Z_3 &= \theta S - (\mu + \omega)V - \frac{\beta' VI}{1+pI}, \\ Z_4 &= \alpha I - \mu R. \end{aligned} \quad (20)$$

220 Then, from (20), we have

$$\begin{aligned} \frac{\partial(DZ_1)}{\partial S} &= -\frac{1}{S^2 I V R} \left[\Lambda + \omega V - \frac{\beta SI}{(1+pI)} - (\mu + \theta)S \right] \\ &\quad + \frac{1}{S I V R} \left[-\frac{\beta I}{(1+pI)} - (\mu + \theta) \right], \\ &= -\frac{(\Lambda + \omega V)}{S^2 I V R} < 0, \end{aligned} \quad (21)$$

$$\begin{aligned}
\frac{\partial(DZ_2)}{\partial I} &= -\frac{1}{SI^2VR} \left[\frac{\beta SI + \beta' VI}{(1+pI)} - (\mu + \alpha)I \right] \\
&\quad + \frac{1}{SIVR} \left[\frac{\beta S + \beta' V}{(1+pI)^2} - (\mu + \alpha) \right], \\
&\quad - \frac{p(\beta S + \beta' V)}{SVR(1+pI)^2} < 0,
\end{aligned} \tag{22}$$

$$\begin{aligned}
\frac{\partial(DZ_3)}{\partial I} &= -\frac{1}{SIV^2R} \left[\theta S - (\mu + \omega)V - \frac{\beta' VI}{(1+pI)} \right] \\
&\quad + \frac{1}{SIVR} \left[-(\mu + \omega) - \frac{\beta' I}{(1+pI)} \right], \\
&\quad - \frac{\theta S}{SIV^2R} < 0,
\end{aligned} \tag{23}$$

$$\begin{aligned}
\frac{\partial(DZ_4)}{\partial I} &= -\frac{1}{SIVR^2}(\alpha I - \mu R) + \frac{1}{SIVR}(-\mu), \\
&\quad - \frac{\alpha I}{SIVR^2} < 0.
\end{aligned} \tag{24}$$

221 From the inequalities (21)-(24), we find

$$\frac{\partial(DZ_1)}{\partial S} + \frac{\partial(DZ_2)}{\partial I} + \frac{\partial(DZ_3)}{\partial V} + \frac{\partial(DZ_4)}{\partial R} < 0. \tag{25}$$

222 Thus, every positive solution of the system (1) tends to the endemic equilibrium
223 E^* when $R_0 > 1$. According to the Dulac–Bendixson theorem, there exists no
224 periodic orbit for (1), and hence the system is globally asymptotically stable for
225 E^* . \square

226 **7 The optimal control model**

227 Control theoretic study plays a pivotal role in the minimization of different in-
228 fectious diseases. We use optimization techniques to develop an optimal control
229 mechanism that minimizes the transmission of the novel Zika virus. We have in-
230 corporated the combination of two control parameters/variables as symbolized
231 by $u(t)$ and define it as $u(t) = \{u_1(t), u_2(t)\}$. Physically or biologically these
232 control measures represent the reverse transcript inhibitor, and the control min-
233 imizing the reservoir contribution to the virus. We place the control functions

234 into the model (1) which leads to the following state system:

$$\begin{aligned}
\frac{dS}{dt} &= \Lambda + \omega V - \frac{\beta SI}{\{1 + (1 - u_2)pI\}} - \{\mu + (1 - u_1)\theta\}S, \\
\frac{dI}{dt} &= \frac{\beta SI}{\{1 + (1 - u_2)pI\}} + \frac{\beta' VI}{\{1 + (1 - u_2)pI\}} - (\mu + \alpha)I, \\
\frac{dV}{dt} &= (1 - u_1)\theta S - (\mu + \omega)V - \frac{\beta' VI}{\{1 + (1 - u_2)pI\}}, \\
\frac{dR}{dt} &= \alpha I - \mu R.
\end{aligned} \tag{26}$$

235 where the initial conditions are

$$S = S_0, \quad I = I_0, \quad V = V_0, \quad R = R_0. \tag{27}$$

236 We define the objective cost function as follows:

$$J[u, x] = \int_0^{t_f} (Au_1^2 + Bu_2^2 + CI^2)dt \tag{28}$$

237 Here the main aim is to minimize the cost function subject to the state system
238 (26).

239 In the objective function described by (28), where $x = (S, I, V, R)$ and
240 A, B and C, are the positive constants called weight constants. The weight-
241 ing constants I are the relative costs of infection and virus, while A and B are
242 the weighting constants that measure the associated cost of the control variables
243 $u_1(t)$ and $u_2(t)$ respectively.

244 We have to find the optimal control function represented by (u_1^*, u_2^*) such
245 that

$$J(u_1^*, u_2^*) = \min\{J(u_1, u_2), u_i \in \mathcal{U}, \text{ for } i = 1, 2\}, \tag{29}$$

246 subject to the state system (26) and the control set \mathcal{U} is described as:

$$\mathcal{U} = \{(u_1, u_2,) : u_i \text{ is Lebesgue measurable and } 0 \leq u_i(t) \leq 1, i = 1, 2\}. \tag{30}$$

247 where \mathcal{U} is the control set. The basic concept of an optimal control problem
248 is to prove the existence of optimal control through an optimality system [14].
249 Here we prove the existence condition of optimal control problem by using the
250 approach of Fleming and Rishel [8].

251 Further to proceed, the existence of such control measures variables will be
252 shown. The existence of a system is subjected to the boundedness of the controls
253 as well as Lebesgue measurable, and the initial data non-negativity. Thus the
254 control problem may take the form:

$$\frac{dX}{dt} = PX + Q(X). \tag{31}$$

255 where $X = (S, I, V, R)'$, and the matrices P and $Q(X)$ respectively containing
256 the linear and nonlinear bounded coefficients are given by the following:

257 **Theorem 6.** *There exists an optimal solution $u^* = (u_1^*, u_2^*) \in \mathcal{U}$ to the control*
 258 *problem (42).*

259 *Proof.* Clearly, the state and control variables have non-negative values. Fur-
 260 thermore, the set of control \mathcal{U} is closed and convex. Moreover, the boundedness
 261 of the control system leads to its compactness. The integral functional (28) is
 262 also convex. Therefore, optimal controls exist. \square

263 7.1 Methodology

264 Let the control input $u^*(t)$ denote the quantity of the drug dose at time t . The
 265 cost function (28) subject to the system of ODE (26) represents the necessary
 266 conditions for which an optimal control and corresponding states must sat-
 267 isfy Pontryagin's Maximum Principle. To determine the optimal control $u_1^*(t)$
 268 and $u_2^*(t)$, we use Pontryagin's maximum principle [14]. With the aid of this
 269 principle, we change the system (42) and the cost function (28) into a mini-
 270 mizing problem by constructing the Hamiltonian function H with respect to
 271 $(u_1(t), u_2(t))$.

272 We find the optimal values to the problem described by (28) subject to
 273 the control system (26). For that, the Lagrangian, as well as the Hamiltonian
 274 associated with the control problem, will be defined. Therefore, we take the
 275 state variable x and control variable u to define the Lagrangian (\mathcal{L}) as

$$\mathcal{L} = Au_1^2 + Bu_2^2 + CI. \quad (32)$$

276 Using the adjoint variables together with the state variables, the Hamiltonian
 277 is constructed as follows:

$$\begin{aligned} \mathcal{H} = & Au_1^2 + Bu_2^2 + CI^2 \\ & + \lambda_1 \left[\Lambda + \omega V - \frac{\beta SI}{\{1 + (1 - u_2)pI\}} - \{\mu + (1 - u_1)\theta\}S \right] \\ & + \lambda_2 \left[\frac{\beta SI}{\{1 + (1 - u_2)pI\}} + \frac{\beta' VI}{\{1 + (1 - u_2)pI\}} - (\mu + \alpha)I \right] \\ & + \lambda_3 \left[(1 - u_1)\theta S - (\mu + \omega)V - \frac{\beta' VI}{\{1 + (1 - u_2)pI\}} \right] \\ & + \lambda_4(\alpha I - \mu R). \end{aligned} \quad (33)$$

278 Here, ξ_i , $i = 1, 2, 3, 4$ denote the adjoint variables, P and Q are the weight
 279 constants, and A represents the penalty multiplier.

280 From (33), we have

$$\begin{aligned}
\frac{\partial \mathcal{H}}{\partial S} &= \frac{\beta I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_1) - \lambda_1\{\mu + (1 - u_1)\theta\} + \lambda_3(1 - u_1)\theta, \\
\frac{\partial \mathcal{H}}{\partial I} &= 2CI + \frac{\beta S}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) + \frac{\beta' V}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3) - \lambda_2(\mu + \alpha) + \lambda_4(\alpha), \\
\frac{\partial \mathcal{H}}{\partial V} &= \lambda_1\omega + \frac{\beta' I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_3) - \lambda_3(\mu + \omega), \\
\frac{\partial \mathcal{H}}{\partial R} &= \lambda_4(-\mu), \\
\frac{\partial \mathcal{H}}{\partial u_1} &= 2Au_1 + \theta S(\lambda_1 - \lambda_3), \\
\frac{\partial \mathcal{H}}{\partial u_2} &= 2Bu_2 + \frac{\beta SpI^2}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) + \frac{\beta' VpI^2}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3).
\end{aligned} \tag{34}$$

281 According to Pontryagin's minimum principle, the adjoint variables satisfy,

$$\frac{d\xi}{dt} = -\frac{\partial \mathcal{H}}{\partial x}. \tag{35}$$

282 Therefore, using (35), the adjoint system evaluated at optimal controls input
283 $(u_1(t), u_2(t))$ and corresponding to the model state variables (S, I, V, R) is ob-
284 tained as:

$$\begin{aligned}
\frac{d\lambda_1}{dt} &= -\left[\frac{\beta I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_1) - \lambda_1\{\mu + (1 - u_1)\theta\} + \lambda_3(1 - u_1)\theta \right], \\
\frac{d\lambda_2}{dt} &= -\left[2CI + \frac{\beta S}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) + \frac{\beta' V}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3) - \lambda_2(\mu + \alpha) + \lambda_4(\alpha) \right], \\
\frac{d\lambda_3}{dt} &= -\left[\lambda_1\omega + \frac{\beta' I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_3) - \lambda_3(\mu + \omega) \right], \\
\frac{d\lambda_4}{dt} &= -[\lambda_4(-\mu)].
\end{aligned} \tag{36}$$

285 The transversality conditions are $\lambda_1(t_f) = 0$, $\lambda_2(t_f) = 0$, $\lambda_3(t_f) = 0$, $\lambda_4(t_f) =$
286 0 . Now Pontryagin's Maximum Principle [14] states that the unconstrained op-
287 timal control $u^*(t)$ satisfies

$$\frac{\partial H}{\partial u(t)} = 0. \tag{37}$$

288 This gives,

$$\begin{aligned}
\frac{\partial \mathcal{H}}{\partial u_1} &= 2Au_1 + \theta S(\lambda_1 - \lambda_3) = 0, \\
\frac{\partial \mathcal{H}}{\partial u_2} &= 2Bu_2 + \frac{\beta SpI^2}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) \\
&\quad + \frac{\beta' VpI^2}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3) = 0.
\end{aligned} \tag{38}$$

289 Solving (38) these for optimal control, we obtain

$$\begin{aligned}
u_1^*(t) &= \frac{(\lambda_3 - \lambda_1)\theta S}{2A}, \\
u_2^*(t) &= \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B},
\end{aligned} \tag{39}$$

290 where,

$$K = \frac{\beta SpI^2}{\{1 + (1 - u_2)pI\}^2}, \quad K' = \frac{\beta' VpI^2}{\{1 + (1 - u_2)pI\}^2}.$$

291 Since the standard control is bounded, we conclude for the control $u_1(t)$, $u_2(t)$:

$$u_1^*(t) = \begin{cases} 0, & \frac{(\lambda_3 - \lambda_1)\theta S}{2A} < 0, \\ \frac{(\lambda_3 - \lambda_1)\theta S}{2A}, & 0 < \frac{(\lambda_3 - \lambda_1)\theta S}{2A} < 1, \\ 1, & \frac{(\lambda_3 - \lambda_1)\theta S}{2A} > 1. \end{cases} \tag{40}$$

$$u_2^*(t) = \begin{cases} 0, & \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} < 0, \\ \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B}, & 0 < \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} < 1, \\ 1, & \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} > 1. \end{cases} \tag{41}$$

292 Hence the compact form of $u_1^*(t)$ is

$$u_1^*(t) = \max \left(\min \left(1, \frac{(\lambda_3 - \lambda_1)\theta S}{2A} \right), 0 \right).$$

293 Similarly, we can obtain the compact form of $u_2^*(t)$ in the form of.

$$u_2^*(t) = \max \left(\min \left(1, \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} \right), 0 \right).$$

294 Utilizing the equation and taking the state system along with the adjoint system,
295 and the transversality conditions, we have the following optimal system:

$$\begin{aligned}
\frac{dS}{dt} &= \Lambda + \omega V - \frac{\beta SI}{\{1 + (1 - u_2)pI\}} - \{\mu + (1 - u_1)\theta\}S, \\
\frac{dI}{dt} &= \frac{\beta SI}{\{1 + (1 - u_2)pI\}} + \frac{\beta'VI}{\{1 + (1 - u_2)pI\}} - (\mu + \alpha)I, \\
\frac{dV}{dt} &= (1 - u_1)\theta S - (\mu + \omega)V - \frac{\beta'VI}{\{1 + (1 - u_2)pI\}}, \\
\frac{dR}{dt} &= \alpha I - \mu R, \\
\frac{d\lambda_1}{dt} &= - \left[\frac{\beta I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_1) - \lambda_1\{\mu + (1 - u_1)\theta\} + \lambda_3(1 - u_1)\theta \right], \\
\frac{d\lambda_2}{dt} &= - \left[2CI + \frac{\beta S}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) + \frac{\beta'V}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3) - \lambda_2(\mu + \alpha) + \lambda_4(\alpha) \right], \\
\frac{d\lambda_3}{dt} &= - \left[\lambda_1\omega + \frac{\beta' I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_3) - \lambda_3(\mu + \omega) \right], \\
\frac{d\lambda_4}{dt} &= - [\lambda_4(-\mu)].
\end{aligned} \tag{42}$$

296 with the initial conditions as: $S(0) > 0$, $I(0) > 0$, $V(0) > 0$, $R(0) > 0$. and
297 boundary conditions as: $\lambda_i(t_f) = 0$, $i = 1, 2, 3, 4$.

298 8 Conclusion

299 In this study, we focused on the role during Zika-virus-Infection in our inves-
300 tigation. Furthermore, a deterministic SEIVR Zika epidemic model is created,
301 investigated, and analysed, utilising nonlinear stability and optimal control the-
302 ory. Hier, the proposed model's positivity and boundedness are examined. Using
303 a next-generation matrix approach, we were able to determine the fundamental
304 reproduction number. The steady-state analysis demonstrates that, if the ba-
305 sic reproduction number R'_o is smaller than unity, the disease-free equilibrium
306 (DFE) ist globally asymptotically stable. Endemic equilibrium is locally asymp-
307 totically stable, if the fundamental reproduction number R'_o is bigger than 1.
308 It is a requirement that the reproduction number be fewer than one, in order
309 to eradicate the zikavirus from the populace. Of course, we cannot take into
310 account all such considerations in order to avoid complexity. However, we plan
311 to consider these options in our future work.

312 References

- 313 [1] D Aldila, K Rasyiqah, G Ardaneswari, and H Tasman. A mathematical
314 model of zika disease by considering transition from the asymptomatic to
315 symptomatic phase. In *Journal of Physics: Conference Series*, volume
316 1821, page 012001. IOP Publishing, 2021.

- 317 [2] Aatif Ali, Saeed Islam, M Riaz Khan, Saim Rasheed, FM Allehiany, Jamel
318 Baili, Muhammad Altaf Khan, and Hijaz Ahmad. Dynamics of a frac-
319 tional order zika virus model with mutant. *Alexandria Engineering Journal*,
320 61(6):4821–4836, 2022.
- 321 [3] Ebraheem O Alzahrani, Wisal Ahmad, Muhammad Altaf Khan, and
322 Sharaf J Malebary. Optimal control strategies of zika virus model with
323 mutant. *Communications in Nonlinear Science and Numerical Simulation*,
324 93:105532, 2021.
- 325 [4] Veronika Bernhauerová, Veronica V Rezelj, and Marco Vignuzzi. Modelling
326 degradation and replication kinetics of the zika virus in vitro infection.
327 *Viruses*, 12(5):547, 2020.
- 328 [5] Sudhanshu Kumar Biswas, Uttam Ghosh, and Susmita Sarkar. Mathe-
329 matical model of zika virus dynamics with vector control and sensitivity
330 analysis. *Infectious Disease Modelling*, 5:23–41, 2020.
- 331 [6] Ebenezer Bonyah, Muhammad Altaf Khan, Kazeem Oare Okosun, and
332 JF Gómez-Aguilar. On the co-infection of dengue fever and zika virus.
333 *Optimal Control Applications and Methods*, 40(3):394–421, 2019.
- 334 [7] Renata Gois de Mello, Thaissa Consoni Bernardino, Luis Giovanni Oliveira
335 Guardalini, Renato Mancini Astray, Marta Maria Antoniazzi, Simone
336 Gonçalves Silva Jared, Eutimio Gustavo Fernández Núñez, and Soraia At-
337 tie Calil Jorge. Zika virus-like particles (vlps) produced in insect cells.
338 *Frontiers in Pharmacology*, 14:1181566, 2023.
- 339 [8] Wendell H Fleming and Raymond W Rishel. *Deterministic and stochastic*
340 *optimal control*, volume 1. Springer Science & Business Media, 2012.
- 341 [9] Gilberto González-Parra, Miguel Díaz-Rodríguez, and Abraham J Arenas.
342 Optimization of the controls against the spread of zika virus in populations.
343 *Computation*, 8(3):76, 2020.
- 344 [10] Jane M Heffernan, Robert J Smith, and Lindi M Wahl. Perspectives on the
345 basic reproductive ratio. *Journal of the Royal Society Interface*, 2(4):281–
346 293, 2005.
- 347 [11] MA Khan, Syed Wasim Shah, Saif Ullah, and JF Gómez-Aguilar. A dy-
348 namical model of asymptomatic carrier zika virus with optimal control
349 strategies. *Nonlinear Analysis: Real World Applications*, 50:144–170, 2019.
- 350 [12] Kumpati S Narendra and Robert Shorten. Hurwitz stability of metzler ma-
351 trices. *IEEE Transactions on Automatic Control*, 55(6):1484–1487, 2010.
- 352 [13] Rhoda Nwalozie, Roseanne Adah Ikpeama, Brenda Anyakwe Nnokam, and
353 Rose Mary Kaiso Esiere. A review on zika virus: Epidemiology, patho-
354 genesis and clinical outcomes. *International Journal of Pathogen Research*,
355 12(3):35–41, 2023.

- 356 [14] Lev Semenovich Pontryagin. *Mathematical theory of optimal processes*.
357 CRC press, 1987.
- 358 [15] Shahram Rezapour, Hakimeh Mohammadi, and Amin Jajarmi. A new
359 mathematical model for zika virus transmission. *Advances in difference*
360 *equations*, 2020(1):1–15, 2020.
- 361 [16] Naveen Sharma, Ram Singh, Jagdev Singh, and Oscar Castillo. Modeling
362 assumptions, optimal control strategies and mitigation through vaccination
363 to zika virus. *Chaos, Solitons & Fractals*, 150:111137, 2021.
- 364 [17] Pauline Van den Driessche and James Watmough. Reproduction numbers
365 and sub-threshold endemic equilibria for compartmental models of disease
366 transmission. *Mathematical biosciences*, 180(1-2):29–48, 2002.
- 367 [18] Xia Wang, Mingwang Shen, Yanni Xiao, and Libin Rong. Optimal control
368 and cost-effectiveness analysis of a zika virus infection model with compre-
369 hensive interventions. *Applied Mathematics and Computation*, 359:165–185,
370 2019.